The Pharmacy Times® Breast Cancer resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Since 2015, there has been an increase in the number of specialty pharmacies in the United States due to their potential of handling the complexities of cost and appropriate drug access and administration.
Early and frequent screenings for childhood cancer survivors could cut breast cancer mortality by well over half.
A potential correlation between processed food and breast cancer has been discovered.
According to the FDA, patients should be selected based on an FDA-approved companion diagnostic test.
One in 8 women will develop breast cancer within their lifetime, making it the most commonly diagnosed cancer among women.
Women diagnosed with breast cancer while breastfeeding may receive treatments that decrease milk production or are contraindicated.
Researchers found that replacing 30 minutes of inactivity with exercise significantly reduces the risk of cancer-related death.
The intent of the study was to bring awareness to the medical and nonmedical financial hardships of cancer and how they can impact the use of preventive services, since there is little research available to evaluate this topic, according to the study authors.
Abemaciclib Significantly Reduces Risk of Cancer Recurrence in People With High Risk HR-Positive, HER2-Negative Early Breast Cancer
The most common adverse reactions observed in the monarchE phase 3 trial include diarrhea, neutropenia, fatigue, infections, nausea, abdominal pain, vomiting, anemia, alopecia, decreased appetite, and leukopenia.
The updated guidelines include increased recommended physical activity levels and a growing emphasis on holistic rather than nutrient-based dietary habits.
In the new data cut-offs from both studies, the survival advantages for the combination with fulvestrant and combination with an aromatase inhibitor were shown, but major disadvantages were also evident, according to the IQWiG.
Trastuzumab deruxtecan (T-DXd) (Enhertu) demonstrated strong efficacy in a phase 2 trial for treatment of HER2-positive metastatic breast cancer.